Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eclSCfbwoceVxbxNYfWO

December 13, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • Gilead gets myelofibrosis drug with YM BioSciences buy
    Gilead Sciences is poised to expand its pipeline of cancer and inflammatory drugs with its planned acquisition of YM BioSciences for about $510 million. The acquisition, which is expected to be finalized in the first quarter, covers YM's lead drug candidate for myelofibrosis, CYT387. Gilead, which is developing its own myelofibrosis drug, will initiate a pivotal trial of CYT387 in the second half of next year. Genetic Engineering & Biotechnology News (12/12), Reuters (12/12) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • BIO CEO: Sequestration will hurt the economy and public health
    The NIH, FDA, CDC and National Science Foundation face billions of dollars in budget cuts if Congress fails to agree on a new budget that avoids automatic 8.2% cuts. The results include thousands of jobs lost, slower FDA reviews and lower reimbursements to drugmakers and doctors, leading to retractions in venture capital and an overall slowing of biomedical innovation, experts say. "Making cuts to these programs could actually cost our nation more in the long run," said BIO President and CEO Jim Greenwood. "The unintended consequences could impact our economic health, as well as our public health." Genetic Engineering & Biotechnology News (12/12) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • SynapDx gets $6M boost to conduct autism test study
    SynapDx has obtained $6 million in financing, which it aims to use to support pivotal trials of a blood assay for diagnosing autism spectrum disorders in children as young as 36 months. The company plans to launch a study next year to evaluate the use of the test in validating performance attributes in 600 children who are at risk for ASD. MedCityNews.com (12/11) LinkedInFacebookTwitterEmail this Story
First class, non-stop, global connections.
BIO conferences provide strategic access for the biotech community to accelerate business relationships. We catalyze partnerships through our global portfolio of events, including the world's largest biotech gathering, the BIO International Convention. Learn more about BIO events.
  Industry Deals 
  Food & Agriculture 
  Industrial & Environmental 
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
No problem can withstand the assault of sustained thinking."
--Voltaire,
French writer, historian and philosopher


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information